TABLE 2:

THERAPEUTIC VACCINE CANDIDATES STUDIED BY THE AVEG

 

STUDIES IN HIV-INFECTED VOLUNTEERS

VACCINE CANDIDATE (STRAIN)

PRODUCTION METHOD (VACCINE DEVELOPER) a

AVEG PROTOCOL NUMBER(S)

REFERENCES

VACCINE DOSE (ROUTE)

ADJUVANT

#VACCINES/ #CONTROLS

VACCINATION SCHEDULE-MONTH (EXTENSION)

rgp160 (IIIB)
Vaccinia/Vero cells (IMMUNO-AG)
101
26
50 µg (IM)
Aluminum Hydroxide + Deoxycholate

30/25

0, 1, 2, 3, 4, 5 or 0, 1, 2, 5
rgp160 (LAI)
Baculovirus/insect cells (MicroGeneSys)
102
NA
640 µg (IM)
Aluminum Phosphate

1/1

5 monthly injections during pregnancy; (3, 6, 9, 12 months post partum)
ENV 2-3 (SF-2)
Yeast derived recombinant envelope protein (BIOCINE)
103, 103A, 103B
27
0, 30 µg ENV 2-3 (IM)
MF59 ± MTP-PE (0, 10, 50, 100 µg MTP-PE)

41/12

0, 1, 4 (7, 10)
rgp120 (MN)
CHO cells (Genentech)
104
28
300 µg (IM)
Aluminum Hydroxide

16/8

5 monthly injections during pregnancy; (3, 6, 9, 12 months post partum)

d Note that the vaccine developer is listed as the company name at the time of protocol initiation. Refer to the participant listings section for changes to company names which have occurred over time.